<< Back to podcast list Strategic Partner(s) Murat Tunaboylu & Ben Holland About Murat Tunaboylu "Murat GPCR About Ben Holland "Ben gained his masters in Engineering Science from Oxford, taking a specialisation nearly 10 years, applying it to antibody generation, analysis, and property prediction since 2017" Ben

GPCR scientist Ben Clements shares how positive allosteric modulators could transform opioid therapy From Aspirations to Application: Ben’s Path into Science Ben shares his winding yet deliberate entry We produce great data, but we also joke around. That’s how we work best.” About Ben Clements Dr. Ben Clements on the web University of Michigan X Google Scholar LinkedIn Unlock the Full Dr.

Benjamin Myers Ben Myers is an assistant professor at the University of Utah School of Medicine in Salt Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic More recently, Ben’s lab has begun studying GPCR signaling pathways that operate within the primary cilium Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure

Her lab studies chemokine receptor CCR1 in multiple myeloma and cancer-to-bone metastasis, free fatty An inverse agonist where none had been reported - constitutive beta-arrestin coupling at FFA2 Gilchrist's Almost no company with an approved GPCR-targeting drug has gone back to look at what common receptor The question that followed was immediate: why hadn't anyone done the same with G-protein C-termini? single reading of someone else's work and a recognition that an obvious experiment had not yet been done

that changed the direction of a lab 47:30 The future of the GPCR superfamily and the work still to be done "Nature decided, for reasons that none of us will ever probably know for sure, that GPCRs should be the physiology, receptor molecular pharmacology in cells, and animal models, and as he puts it has now he’s "gone

Receptor Selectivity The parathyroid hormone receptor sits at the intersection of calcium homeostasis, bone focus on the parathyroid hormone receptor and its downstream consequences for calcium homeostasis and bone PTH-based therapies is hypercalcemia, driven in part by receptor activity in kidney tissue rather than bone Connecting a ligand to a tissue-targeted nanobody could restrict receptor activation to bone and reduce protease stability, and receptor conformation selectivity 21:40 PTH receptor pharmacology: calcium spikes, bone

. << Back to podcast list Strategic Partner(s) Jane Lamerdin and Gaurav Agrawal: Building GPCR Assays About the Guests Jane Lamerdin is VP of R&D at Eurofins DiscoverX, where she oversees development of I like to call myself a jack of all trades, maybe master of none, but enough to be dangerous.

Cone’s lab was a clear choice for a postdoc. Dr. Cone was the first to clone the melanocortin receptors (the GPCRs that led to the discovery of MRAP2)

parathyroid glands of patients with hyperparathyroidism and their impact on body calcium homeostasis and bone

to drug discovery is grounded in classical physiology and driven by a willingness to enter fields - bone professional cost that nobody warns you about Moving between neuroscience, reproductive endocrinology, bone

Anita Nivedha I think it's really well done.

01:55 What pharmacologists bring to drug discovery that nobody else does SELECTED QUOTES "If you've done all the controls appropriately, and you've done the experiments to the best of your ability, and you've

Her current research focuses on how metabolic GPCRs cross-talk and interact to regulate appetite and bone

. 👉 This is where str Attila Foris Feb 23 The Moment Biotech Founders Realize the Money Is Gone 👉 Most

entrepreneurial lessons no one tells postdocs: how to pitch, fail, and build a team Why asking “what if it can be done

They also highlighted the need for a work-life balance and the joy of a well-done job.

She has done extensive work on the molecular pharmacology of opioid receptors and is currently focusing

A Long-Term Vision Realized “We've done this work for the past 30 years.” – Tom Sakmar Dr.

students — especially international students far from their families — connected to a lab that has gone

Not casual, not opinion-writing; dry-lab pharmacology done with the same seriousness as bench work, just

Serendipity and Risk in Discovery — From the accidental observation of GPCR dimers to negative controls gone Pointed Forward The Trevena biased agonist for the AT1 receptor failed in clinical trials, meeting none

receptor genes - yet they govern a disproportionately wide range of physiology, from calcitonin-mediated bone

conformations — how the same ligand can behave as agonist or inverse agonist depending on receptor tone Graciela has done extensive work on the molecular pharmacology of opioid receptors, exploring their signaling

spider toxin binding site — on adhesion GPCRs, synapse formation, and building a research program where none biochemistry, cell biology, and translational thinking could do something that wasn't already being done